Lyell Immunopharma, Inc. (LYEL)
24.00
+0.99
(+4.30%)
USD |
NASDAQ |
Feb 27, 16:00
24.98
+0.98
(+4.08%)
Pre-Market: 20:00
Lyell Immunopharma EPS Diluted (Quarterly) : -2.126 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Insmed, Inc. | -1.538 |
| Nektar Therapeutics | -1.875 |
| GT Biopharma, Inc. | -0.8268 |
| Regeneron Pharmaceuticals, Inc. | 7.857 |
| Vertex Pharmaceuticals, Inc. | 4.651 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -38.85M |
| Revenue (Quarterly) | 0.015M |
| Total Expenses (Quarterly) | 38.86M |
| Enterprise Value | 88.84M |
| Gross Profit Margin (Quarterly) | -17.01K% |
| Profit Margin (Quarterly) | -259.0K% |
| Earnings Yield | -81.63% |
| Normalized Earnings Yield | -50.02 |